Form 4: Alnylam Pharmaceuticals Director Margaret A. Hamburg Reports Stock and Option Grant

Director Margaret A. Hamburg reports the acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• On May 8, 2025, Margaret A. Hamburg, a director of Alnylam Pharmaceuticals, reported the acquisition of 775 shares of common stock represented by restricted stock units (RSUs) and 1,558 stock options.
• The RSUs were granted under the Amended and Restated 2018 Stock Incentive Plan and each RSU represents a contingent right to receive one share of common stock.
• The RSUs and stock options will vest in full upon the earlier of the first anniversary of the grant date (May 8, 2026) or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• The exercise price of the stock options is $258.35.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (grant of stock options and RSUs) which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, particularly in the biotech industry, to align their interests with shareholders.

Comparison to Industry Standards

• Granting stock options and RSUs to directors is a common practice among publicly traded companies, especially in the pharmaceutical and biotechnology sectors.
• Companies like Moderna, BioNTech, and CRISPR Therapeutics also utilize equity-based compensation for their board members.
• The vesting schedules and terms are generally in line with industry standards, aiming to incentivize long-term commitment and alignment with shareholder value.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Alnylam Pharmaceuticals, Director, Margaret A. Hamburg, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership